Abstract

Estrogen receptors (ERα and ERβ) in the brain play critical roles in maintaining brain tissue homeostasis and in tissue repair after injury. Growth of cancer metastasis in the brain is a constant damaging process. The role of ERs of the host in the progression of cancer brain metastasis is unknown. To determine the role of ERβ of host in the progression of lung cancer brain metastasis, we used an isogenic murine lung cancer cell line, Lewis lung carcinoma cells (3LL), to produce orthotopic lung cancer brain metastases in wild type and ERβ knockout (ERβ-/-) mice. In the wild type mice, we found that ERα and ERβ appeared in the tumor associated reactive astrocytes at 24hr after injection of tumor cells, and ERβ remained thereafter while ERα disappeared after 1 week. The metastasis bearing ERβ-/- mice survived significantly longer than the wild type mice. To further test the role of ERβ of reactive astrocytes in the survival of cancer cells, we knocked down ERβ in cultured actrocytes using shRNA and performed 3D co-culture with 3LL cells in the presence/absence of chemotherapeutic agents, oxaliplatin and 5-fluorouracil. We found that loss of ERβ in astrocytes significantly reduced the survivability of 3LL cells co-cultured with astrocytes. It is concluded that ERβ of host, especially ERβ in reactive astrocytes, promotes the progression of lung cancer brain metastasis and ERβ might be a potential therapeutic target for lung cancer brain metastasis.

Highlights

  • The development of brain metastasis in lung cancer patients is highly fatal

  • In the wild type mice, we found that estrogen receptor α (ERα) and ERβ appeared in the tumor associated reactive astrocytes at 24 hr after injection of tumor cells, and ERβ remained thereafter while ERα disappeared after 1 week

  • One is that the cancer cells that can grow in the brain environment are a selected subpopulation of cells that are chemoresistant; the other possibility is that the brain microenvironment confers drug resistance to tumor cells

Read more

Summary

Introduction

The development of brain metastasis in lung cancer patients is highly fatal. In the USA, 50% - 60% of lung cancer patients will develop brain metastasis [1]. The resistance of brain metastasis to chemotherapy has been attributed to the blood-brain-barrier (BBB) [3]. It has been found that tumor cells in brain metastasis produce VEGF/VPF which renders the BBB permeable [4]. There are two other non-mutually exclusive mechanisms that may be responsible for the chemoresistance of brain metastases. One is that the cancer cells that can grow in the brain environment are a selected subpopulation of cells that are chemoresistant; the other possibility is that the brain microenvironment confers drug resistance to tumor cells

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.